cisplatin
Showing 1 - 8 of 8
HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine
Recruiting
- HER2-negative Breast Cancer
- +5 more
- Camrelizumab with vinorelbine and cisplatin
-
Beijing, Beijing, ChinaPeking University First Hospital
Oct 15, 2022
Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage Trial in Guangzhou (Olanzapine Tablets, Placebo)
Recruiting
- Olanzapine
- +3 more
- Olanzapine Tablets
- Placebo
-
Guangzhou, Guangdong, ChinaSun Yat-sen University
Feb 14, 2022
Urothelial Carcinoma, Anlotinib, Urogenital Tumors Trial in Tianjin (Anlotinib, Cisplatin, Carboplatin)
Not yet recruiting
- Urothelial Carcinoma
- +6 more
- Anlotinib
- +3 more
-
Tianjin, ChinaTianjin Medical Unversity Second Hospital
Aug 30, 2021
Adenoid Cystic Carcinomas, Cisplatin Trial in Shanghai (Chidamide combined with cisplatin)
Completed
- Adenoid Cystic Carcinomas
- Cisplatin
- Chidamide combined with cisplatin
-
Shanghai, Shanghai, ChinaKai Xue
Aug 18, 2021
Cholangiocarcinoma, Biliary Tract Cancer, Adjuvant Chemo Trial in Seoul (Gemcitabine plus cisplatin, Capecitabine)
Recruiting
- Cholangiocarcinoma
- +5 more
- Gemcitabine plus cisplatin
- Capecitabine
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Jun 13, 2020
Cisplatin, Carboplatin, NPC Trial in Guangzhou (Docetaxel,Carboplatin, Docetaxel,Cisplatin, Carboplatin-based concurrent
Recruiting
- Cisplatin
- +2 more
- Docetaxel,Carboplatin
- +3 more
-
Guangzhou, Guangdong, ChinaSouthern medical university
Apr 14, 2019
Chidamide, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse Trial in Shanghai (Chidamide combined with R-GDP)
Unknown status
- Chidamide
- +15 more
- Chidamide combined with R-GDP
-
Shanghai, Shanghai, China
- +1 more
Dec 12, 2017
Cisplatin, Ototoxicity, Intratympanic Steroids Trial in Safed (Intra-tympanic Cisplatinum)
Unknown status
- Cisplatin
- +2 more
- Intra-tympanic Cisplatinum
-
Safed, IsraelZiv Medical Center
Jan 27, 2011